Ascletis Pharma (HKG:1672) said Wednesday it has observed positive topline results from its U.S. single ascending dose study of ASC30 oral tablet in patients with obesity, a same-day bourse filing said.
The ASC30 oral tablet was generally safe and well tolerated in the Phase Ia study.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.